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Available online 31 August 2015AbstractA clinical practice-based observational study was performed to compare the outcome of alendronate (ALN) and teriparatide (TPTD)
treatment among Japanese postmenopausal women with a history of fragility fractures. Sixty-one Japanese postmenopausal women with a
history of fragility fractures were treated with ALN (35 mg weekly, n ¼ 32) or TPTD (20 mg daily, n ¼ 29) for 2 years in our outpatient clinic.
Alfacalcidol (1 mg daily) was combined with ALN. The lumbar spine or total hip bone mineral density (BMD) was measured using dual energy
X-ray absorptiometry, and bone turnover markers were monitored. ALN decreased the urinary levels of cross-linked N-terminal telopeptides of
type I collagen (NTX) (38.3% after 3 months) and the serum levels of alkaline phosphatase (ALP) (25.7% at 24 months), whereas TPTD
increased the serum levels of intact procollagen type 1 N-terminal propeptide (P1NP) and ALP (79% and 14.1%, respectively at 24 months).
Both ALN and TPTD increased the lumbar spine BMD (8.8% and 15.9%, respectively) and sustained the total hip BMD at 24 months. One
patient treated with ALN experienced vertebral fractures, and one patient treated with TPTD experienced a nonvertebral fracture. These results
confirmed the differential effects of ALN and TPTD on bone turnover and the greater effect of TPTD on the BMD among Japanese post-
menopausal women with a history of fragility fractures.
Copyright © 2015 The Korean Society of Osteoporosis. Production and hosting by Elsevier B.V. This is an open access article under the CC BY-
NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Osteoporosis most commonly affects postmenopausal
women, placing them at a significant risk for fractures.
Alendronate (ALN) is widely used for the treatment of post-
menopausal osteoporosis. ALN reduces the incidence of
vertebral, hip, and wrist fractures in postmenopausal osteo-
porotic women with existing vertebral fractures and the inci-
dence of vertebral fractures in postmenopausal women with* Corresponding author. Institute for Integrated Sports Medicine, Keio
University School of Medicine, 35 Shinanomachi, Shinjuku-ku, Tokyo
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2405-5255/Copyright © 2015 The Korean Society of Osteoporosis. Production and
ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).low bone mineral density (BMD) but without vertebral frac-
tures [1,2]. Teriparatide (TPTD) is used for postmenopausal
women with osteoporosis at a high risk of fractures [3]. TPTD
dramatically increases bone formation and the lumbar spine,
hip, and total-body BMD and effectively reduces the incidence
of vertebral and nonvertebral fractures in postmenopausal
women with osteoporosis [4]. Both medicines appear to be
effective for reducing fragility fractures among post-
menopausal women with established osteoporosis.
A randomized controlled trial (RCT) demonstrated the 1-
year comparative effect of ALN and TPTD on the BMD and
the incidence of nonvertebral fractures in postmenopausal
women with osteoporosis [5]. TPTD is available for up to 2
years in Japan. To our knowledge, however, no data showing
the 2-year comparative effect of ALN and TPTD on the BMDhosting by Elsevier B.V. This is an open access article under the CC BY-NC-
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established osteoporosis have been reported. Thus, a clinical
practice-based observational study was performed to compare
the outcome of ALN and TPTD treatment for a 2-year period
among Japanese postmenopausal women with a history of
fragility fractures. The primary endpoint was the BMD, and
the secondary endpoints were the biochemical markers.
2. Subjects and methods2.1. SubjectsSixty-one postmenopausal women with a history of
fragility fractures (mean age: 70.8 years) were treated with
ALN (35 mg orally, weekly) (n ¼ 32) or TPTD (20 mg sub-
cutaneously, daily) (n ¼ 29) for 2 years at the outpatient clinic
of Keiyu Orthopaedic Hospital (Gunma, Japan) between
March 2011 and December 2014. Alfacalcidol (1 mg orally,
daily) instead of vitamin D supplementation was combined
with ALN, because an RCT clarified the efficacy of ALN
(5 mg daily) plus alfacalcidol (1 mg daily) versus ALN (5 mg
daily) alone in postmenopausal women with severe osteopo-
rosis who were aged 70 years or older and had several risk
factors for incident fractures [6]; the combination therapy with
ALN and alfacalcidol was more effective for fracture pre-
vention in patients with severe vertebral deformity (semi-
quantitative method: grade 3), multiple prevalent vertebral
fractures, and for nonvertebral weight-bearing bone fracture
prevention. Fragility fractures included vertebral, distal radius,
proximal humerus, hip, pelvis, rib or lower leg fractures along
with low BMD (<80% of the young adult mean [YAM]). In
Japan, the %YAM is used instead of the T score for the
diagnosis of primary osteoporosis [7]. The doses indicated in
the parentheses are the doses used in Japan for the treatment of
postmenopausal women with osteoporosis and have been
recognized as being safe and effective [8e10]. The inclusion
criteria were postmenopausal osteoporosis, and the exclusion
criteria were secondary osteoporosis and other diseases that
decrease the BMD [7,11,12]. None of the subjects had ever
taken medication for the treatment of osteoporosis prior to the
present study. Patients selected the treatment (ALN or TPTD)
by themselves after the method of administration and the
prices of the medicines had been explained: the monthly cost
of TPTD (daily subcutaneous injection) and ALN (weekly
internal use) were approximately 52,000 yen and 2600 yen,
respectively. Adverse events of TPTD were explained by
doctors: nausea, headache, and dizziness, and those of ALN
were explained by pharmacists: upper gastrointestinal adverse
events. Patients whose data were missing or incomplete were
excluded, because they were not followed up adequately.
The preliminary screening included a medical history,
physical examination, plain X-rays of the thoracic and lumbar
spine, BMD measurements at the lumbar spine or total hip, and
blood and/or urinary biochemical tests. Dual-energy X-ray
absorptiometry (DXA) was used to measure the BMD of the
lumbar spine or the total hip. The BMDwas primarily measured
at the lumbar spine, but was done at the total hip in patients withsevere spondylosis, callus formation after vertebral fractures,
and severe aortic calcification, which were thought to signifi-
cantly affect the lumbar spine BMD. Thus, the lumbar spine
BMD was measured in 55 patients and the total hip BMD was
measured in 6 patients. Biochemical tests included measure-
ments of the serum levels of calcium, phosphorus, and alkaline
phosphatase (ALP) in the ALN and TPTD groups. The urinary
levels of cross-linked N-terminal telopeptides of type I collagen
(NTX) were measured in the ALN group, while the serum
levels of intact procollagen type 1 N-terminal propeptide
(P1NP) were measured in the TPTD group.
The serum levels of calcium, phosphorus, and ALP and the
lumbar spine or total hip BMD were measured every 6 months
after the start of treatment in both groups. The measurement of
urinary NTX levels is permitted only twice (just before and
within 6 months after the start of medication) in Japan because
of health insurance regulations. Thus, we evaluated urinary
NTX at 3 months after the start of treatment in the ALN group
[13]. The serum intact P1NP levels were measured every 6
months in the TPTD group. After 2 years of treatment, plain
X-rays of the thoracic and lumbar spine were taken to assess
the incidence of vertebral fractures. The incidence of clinical
fractures was also assessed. The outcome of ALN and TPTD
treatment for 2 years was then evaluated. The present study
was approved by the Ethics Committee of Keiyu Orthopaedic
Hospital.2.2. Assessment of vertebral fracturesPlain lateral X-ray films of the thoracic and lumbar spine
were obtained at baseline to detect evidence of morphometric
vertebral fractures. According to the Japanese criteria, a
vertebral fracture was defined according to the vertebral height
on lateral X-ray films [11,12]. Briefly, the vertebral height was
measured at the anterior (A), central (C), and posterior (P)
parts of the vertebral body, and the presence of a vertebral
fracture was confirmed when (1) a reduction in the vertebral
height of more than 20% (A, C, and P) compared with the
height of the adjacent vertebrae was observed, (2) the C/A or
C/P was less than 0.8, or (3) the A/P was less than 0.75. The
assessment for vertebral fractures was performed at the
T4eL4 level.2.3. Assessment of clinical fracturesLow-traumatic osteoporotic clinical fractures were
assessed. In particular, nonvertebral fractures in terms of major
osteoporotic fractures at the distal radius, proximal humerus,
hip, pelvis, rib or lower leg were determined, if any, based on
clinical symptoms and radiographs.2.4. Measurement of lumbar spine or total hip BMDThe BMD of the lumbar spine or the left total hip in the
anteroposterior view was measured using DXAwith a Hologic
QDR Explorer apparatus (Bedford, MA, USA). The inappro-
priate spine within the lumbar (L1eL4) spine for the BMD
Table 1
Baseline characteristics of study subjects.
ALN
(n ¼ 32)
TPTD
(n ¼ 29)
P
values
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cient of variation (100  standard deviation/mean) of five
measurements with repositioning within 72 h each time was
less than 1.2% for three persons.Age (years) 70.9 ± 8.1 70.6 ± 6.8 NS
Height (m) 1.50 ± 0.07 1.48 ± 0.04 NS2.5. Measurements of biochemical markers
Body weight (kg) 49.8 ± 6.8 48.8 ± 7.4 NS
Body mass index (kg/m2) 22.2 ± 2.3 22.2 ± 3.6 NS
Prevalence of vertebral fracture (%) 87.5 96.6 NS
History of nonvertebral fracture (%) 34.4 13.8 NS
Lumbar spine BMD (g/cm2) 0.652 ± 0.082
(n ¼ 30)
0.576 ± 0.123
(n ¼ 25)
<0.01
YAM of lumbar spine BMD (%) 65.4 ± 8.1 57.1 ± 12.3 <0.01
Total hip BMD (g/cm2) 0.430 ± 0.046
(n ¼ 2)
0.619 ± 0.079
(n ¼ 4)
NS
YAM of total hip BMD (%) 52.0 ± 5.7 72.0 ± 18.9 NSThe serum levels of calcium, phosphorus and ALP were
measured using standard laboratory techniques (normal range:
8.4e10.2 mg/dL, 2.5e4.5 mg/dL, and 135e310 IU/L,
respectively). The urinary NTX levels were measured using an
enzyme immunoassay (normal range: 9.3e54.3 nM BCE/mM
Cr). The serum intact P1NP levels were measured using a
radioimmunoassay (normal range: 17.1e64.7 mg/L).Serum calcium (mg/dL) 9.3 ± 0.4 9.1 ± 0.4 NS
Serum phosphorus (mg/dL) 3.2 ± 0.4 3.4 ± 0.5 NS2.6. Statistical analysis
Serum ALP (IU/L) 258 ± 80 258 ± 98 NS
Serum intact PINP (ng/mL) 62.6 ± 28.3
Urinary NTX (nmol BCE/mmol Cr) 53.8 ± 14.2
Data are expressed as the mean ± SD. BMD: bone mineral density, YAM:
young adult mean, ALP: alkaline phosphatase, P1NP: procollagen type 1 N-
terminal propeptide, NTX: cross-linked N-terminal telopeptides of type I
collagen, BCE: bone collagen equivalent, Cr: creatinine.Data were expressed as the mean ± standard deviation (SD)
in the tables and figures. An unpaired t-test or Fisher exact test
was used to compare data between the two groups. A one-way
analysis of variance (ANOVA) with repeated measurements
was used to determine the significance of longitudinal changes
in the BMD and biochemical markers. A two-way ANOVA
with repeated measurements was used to compare the longi-
tudinal changes in the BMD and biochemical markers between
the two groups. The correlations between the increase in the
serum intact P1NP levels after 6 months of treatment and the
increase in the lumbar spine BMD after 12 and 24 months of
treatment were examined using a single regression analysis.
All the statistical analyses were performed using the Stat
View-J5.0 program on a Windows computer. A significance
level of P < 0.05 was used for all the comparisons.
3. Results3.1. Baseline characteristics of study subjectsTable 1 shows that the mean age of the study subjects was
70.9 years in the ALN group and 70.6 years in the TPTD
group. There were no significant differences in the age, height,
body weight, body mass index, prevalence of vertebral frac-
tures, history of nonvertebral fractures, serum calcium, phos-
phorus, or ALP levels between the two groups. Although there
was no significant difference in the total hip BMD because of
the small sample size, the lumbar spine BMD was significantly
lower in the TPTD group than in the ALN group (0.576 g/cm2
vs. 0.652 g/cm2).
Twenty-eight patients (87.5%) in the ALN group and 28
patients (96.6%) in the TPTD group had prevalent vertebral
fractures (morphometric vertebral fractures). In total, 52
vertebral fractures were found in the ALN group, and 72
vertebral fractures in the TPTD group. Thus, the average
numbers of vertebral fractures per patient were 1.63 in the
ALN group and 2.48 in the TPTD group. With regard to the
fracture distribution, vertebral fractures were found at the T7
(n ¼ 1), T8 (n ¼ 3), T9 (n ¼ 2), T10 (n ¼ 1), T11 (n ¼ 2), T12
(n ¼ 13), L1 (n ¼ 8), L2 (n ¼ 11), L3 (n ¼ 4), L4 (n ¼ 5), andL5 (n ¼ 2) in the ALN group, and at the T6 (n ¼ 1), T7
(n ¼ 3), T8 (n ¼ 2), T9 (n ¼ 3), T10 (n ¼ 3), T11 (n ¼ 3), T12
(n ¼ 11), L1 (n ¼ 9), L2 (n ¼ 11), L3 (n ¼ 10), L4 (n ¼ 11),
and L5 (n ¼ 5) in the TPTD group.3.2. Changes in lumbar spine or total hip BMD and
biochemical markersFig. 1 shows the changes in the lumbar spine BMD. The
increases in the lumbar spine BMD after 6, 12, 18, and 24
months of treatment, compared with the baseline values, were
þ4.1%, þ6.1%, þ7.0%, and þ8.8%, respectively, in the ALN
group, while the respective increases were þ7.6%, þ11.9%,
þ14.4%, and þ15.9%, in the TPTD group. A one-way
ANOVA with repeated measurements detected significant in-
creases in the lumbar spine BMD in both groups (Table 2).
The changes in the total hip BMD after 6, 12, 18, and 24
months of treatment, compared with the baseline values, were
þ1.3%, þ1.8%, 1.5%, and þ1.6%, respectively, in the ALN
group, while the respective changes were þ0.5%, þ2.5%,
þ2.8%, and þ2.0%, in the TPTD group. However, a one-way
ANOVA with repeated measurements did not detect any sig-
nificant increases in the total hip BMD in either group (Table
2). A two-way ANOVA with repeated measurements detected
a significant difference in increase in the lumbar spine BMD,
but not total hip BMD, between the two groups (Table 2).
Fig. 1 also shows the changes in bone turnover markers. In
the ALN group, the urinary NTX levels decreased (38.3%
compared with the baseline values) after 3 months of treatment
and the serum ALP levels decreased after 6 months of treat-
ment. The decreases in the serum ALP levels after 6, 12, 18,
and 24 months of treatment, compared with the baseline
values, were 23.4%, 29.9%, 26.2%, and 25.7%,
respectively. A one-way ANOVAwith repeated measurements
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Fig. 1. Changes in lumbar spine BMD and bone turnover markers. Data were expressed as the mean ± SD. A one-way analysis of variance (ANOVA) with repeated
measurements detected a significant increase in the lumbar spine BMD and significant decreases in the urinary levels of NTX and the serum levels of ALP in the
ALN group and significant increases in the lumbar spine BMD and the serum levels of ALP and intact P1NP in the TPTD group (Table 2). A two-way ANOVA
with repeated measurements detected a significant difference in increase in the lumbar spine BMD between the two groups (Table 2). BMD: bone mineral density,
ALP: alkaline phosphatase, NTX: cross-linked N-terminal telopeptides of type I collagen, P1NP: procollagen type 1 N-terminal propeptide.
Table 2
One- and two-way ANOVA with repeated measurements.
One-way ANOVA Two-way ANOVA
(TPTD vs. ALN)
Lumbar BMD TPTD <0.0001 <0.05
ALN <0.0001
Serum ALP TPTD <0.0001 <0.0001
ALN <0.05
Serum calcium TPTD NS NS
ALN NS
Serum phosphorus TPTD NS NS
ALN NS
Serum intact PINP TPTD <0.0001
Urinary NTX ALN <0.0001
A one-way ANOVA with repeated measurements was used to analyze longi-
tudinal changes in BMD and biochemical markers.
A two-way ANOVA with repeated measurements was used to compare lon-
gitudinal changes in BMD and biochemical markers.
BMD: bone mineral density, ALP: alkaline phosphatase, PINP: Procollagen
type I N-terminal propeptides, NTX: cross-linked N-terminal telopeptides of
type I collagen, ANOVA: analysis of variance, NS: not significant.
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ALP levels in the ALN group (Table 2). In the TPTD group,
the serum intact P1NP and ALP levels increased after 6
months of treatment. The increases in the serum intact P1NP
levels after 6, 12, 18, and 24 months of treatment, compared
with the baseline values, were þ121%, þ137%, þ132%, and
þ79%, respectively. The respective increases in the serum
ALP levels were þ19.4%, þ24.9%, þ26.0%, and þ14.1%. A
one-way ANOVA with repeated measurements detectedsignificant increases in the serum intact P1NP and ALP levels
in the TPTD group (Table 2). A two-way ANOVA with
repeated measurements detected a significant difference in
changes in the serum ALP levels between the two groups
(Table 2). However, a one-way ANOVA with repeated mea-
surements did not detect any significant difference in changes
in the serum calcium and phosphorus levels in either group
(Fig. 2), and a two-way ANOVA with repeated measurements
did not detect any significant differences in changes in the
serum calcium and phosphorus levels between the two groups
(Table 2).3.3. Correlations between increases in serum intact
P1NP levels and lumbar spine BMDThe increase in the serum intact P1NP levels after 6 months
of treatment was not significantly correlated with the increases
in the lumbar spine BMD after 12 and 24 months of treatment.3.4. Incident fracturesDuring the 2-year treatment period, one patient experienced
morphometric vertebral fractures and one patient experienced
a nonvertebral fracture (rib fracture).3.5. Adverse eventsNo severe adverse effects were observed among the pa-
tients who continued the treatment for 2 years in either group
[10,14].
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Fig. 2. Changes in serum calcium and phosphorus. Data were expressed as the mean ± SD. A one-way analysis of variance (ANOVA) with repeated measurements
did not detect any significant difference in changes in the serum calcium and phosphorus levels in either group, and a two-way ANOVA with repeated mea-
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The present study confirmed that ALN suppressed bone
turnover, thereby increasing the lumbar spine BMD (8.8%),
while TPTD increased bone formation, thereby increasing the
lumbar spine BMD (15.9%), compared with the baseline
values, over a 2-year treatment period in postmenopausal
women with a history of fragility fractures. The effect of
TPTD on the lumbar spine BMD was greater than that of
ALN. Since there was a significant difference in the baseline
lumbar spine BMD between the two groups, the longitudinal
changes, but not the percentage changes, in the lumbar spine
were compared using a two-way ANOVA with repeated
measurement.
RCTs have shown that ALN (5 mg daily or 35 mg weekly)
decreases the urinary NTX (45% after 3 months of treat-
ment) and serum ALP (approximately 26% after 2 years of
treatment) levels and increases the lumbar spine BMD (þ6.9%
after 2 years of treatment) when administered in combination
with calcium and/or vitamin D supplementation in post-
menopausal Japanese women with osteoporosis [8,15]. In the
present study, alfacalcidol (1 mg daily) was combined with
ALN, since an RCT clarified the efficacy of ALN plus alfa-
calcidol (1 mg daily) versus ALN alone in postmenopausal
women with severe osteoporosis who were aged 70 years or
older and had several risk factors for incident fractures [6].
ALN decreased the urinary NTX levels (38.3% after 3 months)
and the serum ALP levels (25.7% at 24 months), thereby
increasing the lumbar spine BMD (8.8% at 24 months). The
results of the present study were comparable with those of
previous studies [8,15]. Thus, ALN successfully suppressed
bone turnover and increased the lumbar spine BMD, compared
with the baseline values, over the course of a 2-year treatment
period.
A phase III study has shown that TPTD increases the serum
intact P1NP levels (þ76.1% at 24 months), thereby increasing
the lumbar spine BMD (þ13.4% at 24 months) in post-
menopausal women with osteoporosis [10]. The increases in
the lumbar spine BMD (þ7.6%, þ11.9%, þ14.4%, and
þ15.9% after 6, 12, 18, and 24 months of treatment, respec-
tively) observed in the present study were consistent withthose observed in an RCT of TPTD in Japanese patients [10].
However, the increases in the serum intact P1NP levels
(þ121%, þ137%, þ132%, and þ79% after 6, 12, 18, and 24
months of treatment, respectively) observed in the present
study were greater than those (þ87% after one month of
treatment) observed in an RCT of TPTD in Japanese patients
[10]. This discrepancy remains uncertain. The large SDs of the
percentage increases in the serum intact P1NP levels suggest
that the response of this marker to TPTD treatment differed
from patient to patient. A strong relationship has been reported
between an early change in the serum intact P1NP levels (after
1 or 3 months of treatment) and later changes in the lumbar
spine BMD (after 12 months of treatment) during TPTD
therapy in Japanese patients with a high risk of fractures
(r ¼ 0.56, P < 0.01 and r ¼ 0.36, P < 0.01, respectively) [16].
In the present study, however, an increase in the lumbar spine
BMD after 12 months of treatment was not correlated with
increases in the serum intact P1NP levels after 6 months of
treatment. The serum intact P1NP levels should have been
measured after 1 or 3 months of treatment to predict the in-
crease in the lumbar spine BMD.
Calcium and vitamin D supplementation, after an evalua-
tion of the serum 25-hydroxyvitamin D [25(OH)D] levels, is
well-recognized to be important in the treatment of osteopo-
rosis. In Japan, however, calcium and vitamin D supplements
are not widely used, and the measurement of the serum
25(OH)D levels is not covered by health insurance. Epide-
miological studies have indicated a high prevalence of vitamin
D deficiency among postmenopausal Japanese women [17].
Although the vitamin D status was uncertain, the patients in
the present study appeared to respond well to TPTD therapy,
based on the increase in their serum P1NP levels. A post-hoc
analysis of the Fracture Prevention Trial also demonstrated
that the responses to TPTD did not differ significantly between
women with baseline 25(OH)D insufficiency and those with
baseline 25(OH)D sufficiency among postmenopausal women
with osteoporosis and a normal intact parathyroid hormone
[18].
An RCT demonstrated the 1-year comparative effect of
ALN and TPTD on the BMD and bone turnover markers in
postmenopausal women with osteoporosis [5]. TPTD
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value than that induced by ALN (TPTD: 12.2% vs. ALN:
5.6%). TPTD also increased the serum levels of bone-specific
ALP (approximately 100% at 6 months), while ALN
decreased the serum levels of bone-specific ALP and the uri-
nary levels of NTX (both approximately 50% after 3 months).
In the present study, the serum bone-specific ALP levels were
not evaluated; however the changes in the lumbar spine BMD
and bone turnover markers were comparable between the
previous studies and our present study. These results were
supported by a 6-month lumbar spine quantitative computed
tomography (finite element modeling) study and an 18-month
bone histomorphometry (transiliac crest biopsy) study in
postmenopausal women with osteoporosis [19,20]. The former
study demonstrated that both TPTD and ALN increased the
average volumetric density and strength in the trabecular bone,
but that the median percentage increases for these parameters
were 5-folde20-fold greater for TPTD [19]. The latter
confirmed the opposite mechanism of action of TPTD and
ALN on bone remodeling and of TPTD on bone formation
[20].
The strength of the present study was that the 2-year
comparative effect of ALN and TPTD on the BMD and
bone turnover in Japanese postmenopausal women with
established osteoporosis was shown. The notable limitations
were that the study had a clinical practice-based observational
design (retrospective study) and a relatively small sample size,
and that the data was collected based on conventional medical
practices. Thus, selection bias might affect the results of the
study. RCTs with a large number of subjects are needed to
establish the efficacy and safety of ALN and TPTD in Japa-
nese postmenopausal women with established osteoporosis.
In conclusion, the present study confirmed that ALN sup-
pressed bone turnover, thereby increasing the lumbar spine
BMD (8.8%), while TPTD increased bone formation, thereby
increasing the lumbar spine BMD (15.9%), compared with the
baseline values, over a 2-year treatment period in post-
menopausal women with a history of fragility fractures. These
results suggested that ALN and TPTD had differential effects
on bone turnover and that TPTD had a greater effect on the
BMD among Japanese postmenopausal women with a history
of fragility fractures.
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